At a glance
Overview
This monthly dashboard expands on the weekly COVID-19, flu, and RSV data available. It allows users to take a deeper dive into attitudes and behaviors associated with COVID-19, flu, and RSV vaccine uptake by a comprehensive set of demographic characteristics, behavioral and social drivers of vaccination, and barriers to vaccination.
Methods
Vaccination coverage estimates among adults 18 years and older are based on data from CDC's National Immunization Survey–Adult COVID Module. Estimates of vaccination coverage are based on respondent self-report. Estimates of vaccination coverage on this dashboard may vary from estimates on the weekly dashboard; weekly estimates are derived from compiling interview data from all prior weeks, while monthly estimates are derived only from interviews conducted that month.
Data Summary
COVID-19 and influenza vaccines
- As of October 2024, 13.7% of adults 18+ in the U.S. have received a 2024–25 COVID-19 vaccine and 24.5% have received a 2024–25 flu vaccine.
- Coverage is highest among adults 65+ (29.1% and 43.1%, respectively).
- Vaccination coverage varied by jurisdiction, ranging from 3.7% (Puerto Rico) to 24.7% (D.C.) for COVID-19 vaccine, and from 13.6% (Puerto Rico) to 34.9% (Massachusetts) for influenza vaccine.
- Coverage is highest among adults 65+ (29.1% and 43.1%, respectively).
- 16.8% and 22.8% reported they definitely will get vaccinated with a 2024–25 COVID-19 vaccine and a 2024–25 influenza vaccine, respectively.
- Concern about disease, confidence in vaccine safety, and confidence in the importance of the vaccine to prevent disease continue to be drivers of vaccination.
- Adults who expressed moderate to high concern about getting COVID-19 disease are more likely to have received a 2024–25 COVID-19 vaccine compared with adults who express little to no concern (21.4% vs. 9.0%). Adults who consider the vaccines safe and who consider the vaccines important to protect them are also more likely to have received the 2024–25 COVID-19 vaccine (24.0% vs. 2.9% and 20.7% vs. 1.3%, respectively).
- Adults who expressed moderate to high concern about getting flu are more likely to have received a 2024–25 flu vaccine compared with adults who express little to no concern (13.2% vs. 8.6%). Adults who consider the vaccines safe and who consider the vaccines important to protect them are also more likely to have received the 2024–25 vaccine (13.6% vs. 4.7% and 13.4% vs. 2.1%, respectively).
- Adults who expressed moderate to high concern about getting COVID-19 disease are more likely to have received a 2024–25 COVID-19 vaccine compared with adults who express little to no concern (21.4% vs. 9.0%). Adults who consider the vaccines safe and who consider the vaccines important to protect them are also more likely to have received the 2024–25 COVID-19 vaccine (24.0% vs. 2.9% and 20.7% vs. 1.3%, respectively).
- The percent of adults reporting a healthcare provider had recommended vaccination since July 1, 2024, was 19.7% for COVID-19 and 35.3% for influenza vaccination.
- Few (6.2%) adults reported it would be somewhat or very difficult to get a COVID-19 vaccine.
RSV vaccine
- As of October 2024, RSV vaccination coverage was 31.9% among adults aged ≥75 years and 31.5% among those aged 60–74 years at increased risk of severe RSV disease.
- Among adults aged ≥75 years, 12.4% reported that they definitely will be vaccinated against RSV, and 14.2% among those aged 60–74 years at increased risk.
- Among adults aged ≥75 years, 12.4% reported that they definitely will be vaccinated against RSV, and 14.2% among those aged 60–74 years at increased risk.
- RSV vaccination coverage is higher among White, non-Hispanics compared with other races among both adults aged ≥75 years (35.6%) and adults aged 60–74 years at increased risk (36.0%).